High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker
详细信息 查看全文
- 作者：Yakup Kumtepe (1)
Zekai Halici (2)
Ozlem Sengul (3)
Celalettin Semih Kunak (4)
Yasin Bayir (5)
Nergiz Kilic (6)
Elif Cadirci (7)
Alparslan Pulur (1)
Zafer Bayraktutan (8) - 关键词：HTATIP2/TIP30 ; ovarian cancer ; adenocarcinoma
- 刊名：European Journal of Medical Research
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：18
- 期：1
- 全文大小：174KB
- 参考文献：1. Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L, Mills GB: Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. / J Oncol 2010, 2010:568938. CrossRef
2. Feeley KM, Wells M: Precursor lesions of ovarian epithelial malignancy. / Histopathology 2001, 38:87-5. CrossRef
3. Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S, Morrison J: Epidermal growth factor receptor blockers for the treatment of ovarian cancer. / Cochrane Database Syst Rev 2011., 5: CD007927
4. Shepherd JH: Revised FIGO staging for gynecological cancer. / Br J Obstet Gynecol 1989, 96:889-92. CrossRef
5. Baselga J, Albanell J, Molina MA, Arribas J: Mechanism of action of trastuzumab and scientific update. / Semin Oncol 2001, 28:4-1. CrossRef
6. Cooley S, Burns LJ, Repka T, Miller JS: Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. / Exp Hematol 1999, 27:1533-541. CrossRef
7. Chase DM, Mathur N, Tewari KS: Drug discovery in ovarian cancer. / Recent Pat Anticancer Drug Discov 2010, 5:251-60. CrossRef
8. Tomsova M, Melichar B: Contribution of immunohistochemistry in prognostic assessment of epithelial ovarian carcinoma - review of the literature I. / Acta Medica (Hradec Kralove) 2006, 49:161-65.
9. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. / J Clin Oncol 2003, 21:283-90. CrossRef
10. Zhang DH, Wong LL, Tai LK, Koay ES, Hewitt RE: Overexpression of CC3/TIP30 is associated with HER2/neu status in breast cancer. / J Cancer Res Clin Oncol 2005, 131:603-08. CrossRef
11. Xiao H, Tao Y, Greenblatt J, Roeder RG: A cofactor, TIP30, specifically enhances HIV-1 Tat-activated transcription. / Proc Natl Acad Sci USA 1998, 95:2146-151. CrossRef
12. Xiao H, Palhan V, Yang Y, Roeder RG: TIP30 has an intrinsic kinase activity required for up-regulation of a subset of apoptotic genes. / EMBO J 2000, 19:956-63. CrossRef
13. Ito M, Jiang C, Krumm K, Zhang X, Pecha J, Zhao J, Guo Y, Roeder RG, Xiao H: TIP30 deficiency increases susceptibility to tumorigenesis. / Cancer Res 2003, 63:8763-767.
14. NicAmhlaoibh R, Shtivelman E: Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro . / Oncogene 2001, 20:270-75. CrossRef
15. Shi M, Zhang X, Wang P, Zhang HW, Zhang BH, Wu MC: TIP30 regulates apoptosis-related genes in its apoptotic signal transduction pathway. / World J Gastroenterol 2005, 11:221-27.
16. Shtivelman E: A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. / Oncogene 1997, 14:2167-173. CrossRef
17. Zhao J, Zhang X, Shi M, Xu H, Jin J, Ni H, Yang S, Dai J, Wu M, Guo Y: TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU. / Hepatology 2006, 44:205-15. CrossRef
18. Jiang C, Ito M, Piening V, Bruck K, Roeder RG, Xiao H: TIP30 interacts with an estrogen receptor alpha-interacting coactivator CIA and regulates c-Myc transcription. / J Biol Chem 2004, 279:27781-7789. CrossRef
19. Wang S, Zhao B, Zhang S, Ji H: Cloning, expression, purification, and characterization of AmphiTip30, a member of short-chain dehydrogenases/reductases family from the amphioxus Branchiostoma belcheri tsingtauense . / Protein Expr Purif 2008, 57:63-1. CrossRef
20. Tong X, Li K, Luo Z, Lu B, Liu X, Wang T, Pang M, Liang B, Tan M, Wu M, Zhao J, Guo Y: Decreased TIP30 expression promotes tumor metastasis in lung cancer. / Am J Pathol 2009, 174:1931-939. CrossRef
21. Jiao Y, Ou W, Meng F, Zhou H, Wang A: Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. / Mol Cancer 2011, 10:125. CrossRef
22. Whitman S, Wang X, Shalaby R, Shtivelman E: Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis. / Mol Cell Biol 2000, 20:583-93. CrossRef
23. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA: Mechanisms of estrogen action. / Physiol Rev 2001, 81:1535-565.
24. Planas-Silva MD, Shang Y, Donaher JL, Brown M, Weinberg RA: AIB1 enhances estrogen-dependent induction of cyclin D1 expression. / Cancer Res 2001, 61:3858-862.
25. Battey J, Moulding C, Taub R, Murphy W, Stewart T, Potter H, Lenoir G, Leder P: The human c-Myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. / Cell 1983, 34:779-87. CrossRef
26. Dubik D, Shiu RP: Mechanism of estrogen activation of c-Myc oncogene expression. / Oncogene 1992, 7:1587-594.
27. Leder A, Pattengale PK, Kuo A, Stewart TA, Leder P: Consequences of widespread deregulation of the c-Myc gene in transgenic mice: multiple neoplasms and normal development. / Cell 1986, 45:485-95. CrossRef
28. Liao DJ, Dickson RB: c-Myc in breast cancer. / Endocr Relat Cancer 2000, 7:143-64. CrossRef
29. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE: The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. / Oncogene 2000, 19:968-88. CrossRef
30. Cunha GR, Wiesen JF, Werb Z, Young P, Hom YK, Cooke PS, Lubahn DB: Paracrine mechanisms of mouse mammary ductal growth. / Adv Exp Med Biol 2000, 480:93-7. CrossRef - 作者单位：Yakup Kumtepe (1)
Zekai Halici (2)
Ozlem Sengul (3)
Celalettin Semih Kunak (4)
Yasin Bayir (5)
Nergiz Kilic (6)
Elif Cadirci (7)
Alparslan Pulur (1)
Zafer Bayraktutan (8)
1. Department of Obstetrics and Gynecology, Faculty of Medicine, Ataturk University, Erzurum, 25240, Turkey
2. Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, 25240, Turkey
3. Department of Gynecology and Obstetrics, Yenimahalle Government Hospital, Ankara, 06170, Yenimahalle, Turkey
4. Department of Pharmacology, Faculty of Medicine, Giresun University, Giresun, 28100, Turkey
5. Department of Biochemistry, Faculty of Pharmacy, Ataturk University, Erzurum, 25240, Turkey
6. Department of Obstetrics and Gynecology, Faculty of Medicine, Kafkas University, Kars, 36000, Turkey
7. Department of Pharmacology, Faculty of Pharmacy, Ataturk University, Erzurum, 25240, Turkey
8. Department of Biochemistry, Erzurum Region Education and Research Hospital, Erzurum, 25240, Turkey - ISSN：2047-783X
文摘
Background Human HIV-1 TAT interactive protein 2 (HTATIP2/TIP30) is an evolutionarily conserved gene that is expressed ubiquitously in human tissues and some tumor tissues. This protein has been found to be associated with some gynecological cancers; as such, this study aimed to investigate blood HTATIP2/TIP30 levels in patients with ovarian cancer. Methods Twenty-three women with ovarian cancer and 18 patients with various non-cancerous gynecological complaints (for example, dysfunctional uterine bleeding, fibroids, and urinary incontinence) were included in the study. The pathological diagnosis of ovarian cancer was adenocarcinoma. HTATIP2/TIP30 concentration in the patients-blood samples was determined using ELISA kits. Results The HTATIP2/TIP30 level was significantly higher in the cancer group than in the control group (1.84 ± 0.82 versus 0.57 ± 0.13 ng/ml, mean ± SD). Conclusions We demonstrated the potential role of HTATIP2/TIP30 in ovarian cancer for the first time, thereby enlightening future studies targeting HTATIP2/TIP30 in ovarian cancer treatment, diagnosis, and prevention.